| 1. Monge A, Peña MC, Palop JA, Calderó JM, Roca J, García E, Romero G, del Río J, Lasheras B.. (1994) Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties., 37 (9): [PMID:8176710] [10.1021/jm00035a012] |
| 2. Kato S, Morie T, Hino K, Kon T, Naruto S, Yoshida N, Karasawa T, Matsumoto J.. (1990) Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides., 33 (5): [PMID:2139471] [10.1021/jm00167a020] |
| 3. Flynn DL, Zabrowski DL, Becker DP, Nosal R, Villamil CI, Gullikson GW, Moummi C, Yang DC.. (1992) SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype., 35 (8): [PMID:1573641] [10.1021/jm00086a019] |
| 4. Flynn DL, Becker DP, Spangler DP, Nosal R, Gullikson GW, Moummi C, Yang D. (1992) New aza(nor)adamantanes are agonists at the newly identified serotonin 5-HT4 receptor and antagonists at the 5-HT3 receptor, 2 (12): [10.1016/S0960-894X(00)80441-2] |
| 5. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D.. (2003) Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches., 13 (10): [PMID:12729675] [10.1016/s0960-894x(03)00196-3] |
| 6. Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML.. (1998) Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives., 41 (11): [PMID:9599243] [10.1021/jm970857f] |
| 7. Pearlstein R, Vaz R, Rampe D.. (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior., 46 (11): [PMID:12747773] [10.1021/jm0205651] |
| 8. Buchheit KH, Gamse R, Giger R, Hoyer D, Klein F, Klöppner E, Pfannkuche HJ, Mattes H.. (1995) The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site., 38 (13): [PMID:7608898] [10.1021/jm00013a009] |
| 9. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 10. Keserü GM.. (2003) Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods., 13 (16): [PMID:12873512] [10.1016/s0960-894x(03)00492-x] |
| 11. Langlois M, Fischmeister R.. (2003) 5-HT4 receptor ligands: applications and new prospects., 46 (3): [PMID:12540230] [10.1021/jm020099f] |
| 12. Cavalli A, Poluzzi E, De Ponti F, Recanatini M.. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers., 45 (18): [PMID:12190308] [10.1021/jm0208875] |
| 13. Blum E, Buchheit K, Buescher H, Gamse R, Kloeppner E, Meigel H, Papageorgiou C, Waelchli R, Revesz L. (1992) Design and synthesis of novel ligands for the 5-HT3 and the 5-HT4 receptor, 2 (5): [10.1016/S0960-894X(00)80170-5] |
| 14. Kato S, Morie T, Kon T, Yoshida N, Karasawa T, Matsumoto J.. (1991) Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds., 34 (2): [PMID:1995885] [10.1021/jm00106a023] |
| 15. Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S.. (2003) Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity., 46 (5): [PMID:12593651] [10.1021/jm020270n] |
| 16. Rajamani R, Tounge BA, Li J, Reynolds CH.. (2005) A two-state homology model of the hERG K+ channel: application to ligand binding., 15 (6): [PMID:15745831] [10.1016/j.bmcl.2005.01.008] |
| 17. Becker DP, Flynn DL, Shone RL, Gullikson G.. (2004) Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750., 14 (22): [PMID:15482914] [10.1016/j.bmcl.2004.09.005] |
| 18. Tobita M, Nishikawa T, Nagashima R.. (2005) A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors., 15 (11): [PMID:15911273] [10.1016/j.bmcl.2005.03.080] |
| 19. Becker DP, Flynn DL, Moormann AE, Nosal R, Villamil CI, Loeffler R, Gullikson GW, Moummi C, Yang DC.. (2006) Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists., 49 (3): [PMID:16451077] [10.1021/jm0509501] |
| 20. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E.. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model., 51 (2): [PMID:18027916] [10.1021/jm070524a] |
| 21. Imai YN, Ryu S, Oiki S.. (2009) Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach., 52 (6): [PMID:19260734] [10.1021/jm801236n] |
| 22. Jia L, Sun H.. (2008) Support vector machines classification of hERG liabilities based on atom types., 16 (11): [PMID:18448342] [10.1016/j.bmc.2008.04.028] |
| 23. Coi A, Massarelli I, Testai L, Calderone V, Bianucci AM.. (2008) Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation., 43 (11): [PMID:18262683] [10.1016/j.ejmech.2007.12.025] |
| 24. Zachariae U, Giordanetto F, Leach AG.. (2009) Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers., 52 (14): [PMID:19534531] [10.1021/jm900002x] |
| 25. Ermondi G, Visentin S, Caron G.. (2009) GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers., 44 (5): [PMID:19110341] [10.1016/j.ejmech.2008.11.009] |
| 26. McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.. (2009) A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists., 52 (17): [PMID:19663444] [10.1021/jm900881j] |
| 27. Guerra A, Campillo NE, Páez JA.. (2010) Neural computational prediction of oral drug absorption based on CODES 2D descriptors., 45 (3): [PMID:20022146] [10.1016/j.ejmech.2009.11.034] |
| 28. Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO.. (2010) Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration., 45 (4): [PMID:20116902] [10.1016/j.ejmech.2009.12.070] |
| 29. Sinha N, Sen S.. (2011) Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model., 46 (2): [PMID:21185626] [10.1016/j.ejmech.2010.11.042] |
| 30. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 31. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 32. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 33. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 34. Unpublished dataset, |
| 35. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 36. Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.. (2011) QSAR-based permeability model for drug-like compounds., 19 (8): [PMID:21458999] [10.1016/j.bmc.2011.03.011] |
| 37. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 38. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 39. Sun H, Scott DO.. (2011) Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design., 2 (8): [PMID:21841964] [10.1021/ml200117z] |
| 40. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 41. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 42. Furlotti G, Alisi MA, Apicella C, Capezzone de Joannon A, Cazzolla N, Costi R, Cuzzucoli Crucitti G, Garrone B, Iacovo A, Magarò G, Mangano G, Miele G, Ombrato R, Pescatori L, Polenzani L, Rosi F, Vitiello M, Di Santo R.. (2012) Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands., 55 (22): [PMID:23043420] [10.1021/jm300573d] |
| 43. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J.. (2012) Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia., 55 (20): [PMID:23043539] [10.1021/jm300952s] |
| 44. PubChem BioAssay data set, |
| 45. Gozalbes R, Mosulén S, Ortí L, Rodríguez-Díaz J, Carbajo RJ, Melnyk P, Pineda-Lucena A.. (2013) Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches., 21 (7): [PMID:23415087] [10.1016/j.bmc.2013.01.033] |
| 46. McKinnell RM, Armstrong SR, Beattie DT, Fatheree PR, Long DD, Marquess DG, Shaw JP, Vickery RG.. (2013) Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties., 23 (14): [PMID:23756062] [10.1016/j.bmcl.2013.05.018] |
| 47. Tang L, Zhao L, Hong L, Yang F, Sheng R, Chen J, Shi Y, Zhou N, Hu Y.. (2013) Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers., 21 (19): [PMID:23978359] [10.1016/j.bmc.2013.07.051] |
| 48. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 49. PubChem BioAssay data set, |
| 50. Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK.. (2014) Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent., 57 (10): [PMID:24786585] [10.1021/jm500115w] |
| 51. Cao X, Sun Z, Cao Y, Wang R, Cai T, Chu W, Hu W, Yang Y.. (2014) Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility., 57 (9): [PMID:24564525] [10.1021/jm4016284] |
| 52. Castriconi F, Paolino M, Giuliani G, Anzini M, Campiani G, Mennuni L, Sabatini C, Lanza M, Caselli G, De Rienzo F, Menziani MC, Sbraccia M, Molinari P, Costa T, Cappelli A.. (2014) Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold., 82 [PMID:24871995] [10.1016/j.ejmech.2014.05.015] |
| 53. Xia G, Chen W, Zhang J, Shao J, Zhang Y, Huang W, Zhang L, Qi W, Sun X, Li B, Xiang Z, Ma C, Xu J, Deng H, Li Y, Li P, Miao H, Han J, Liu Y, Shen J, Yu Y.. (2014) A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles., 57 (23): [PMID:25409491] [10.1021/jm5014659] |
| 54. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.. (2011) Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk., 91 [PMID:21300721] [10.1093/cvr/cvr044] |
| 55. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.. (2012) Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment., 32 [PMID:22761000] [10.1002/jat.2784] |
| 56. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.. (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes., 3 [PMID:23812503] [10.1038/srep02100] |
| 57. Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.. (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity., 40 (5): [PMID:22328583] [10.1124/dmd.111.043505] |
| 58. Ai Y, Hu Y, Kang F, Lai Y, Jia Y, Huang Z, Peng S, Ji H, Tian J, Zhang Y.. (2015) Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents., 58 (11): [PMID:25992974] [10.1021/jm5020023] |
| 59. Yang W, Li L, Wang Y, Wu X, Li T, Yang N, Su M, Sheng L, Zheng M, Zang Y, Li J, Liu H.. (2015) Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., 23 (17): [PMID:26211462] [10.1016/j.bmc.2015.06.071] |
| 60. Unpublished dataset, |
| 61. WHO Anatomical Therapeutic Chemical Classification, |
| 62. British National Formulary (72nd edition), |
| 63. DrugMatrix, [10.6019/CHEMBL3885881] |
| 64. (2015) Benzamide derivatives, |
| 65. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L.. (2017) Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)., 127 [PMID:28038328] [10.1016/j.ejmech.2016.12.038] |
| 66. Castriconi F, Paolino M, Grisci G, Francini CM, Reale A, Giuliani G, Anzini M, Giorgi G, Mennuni L, Sabatini C, Lanza M, Caselli G, Cappelli A.. (2018) Development of subnanomolar-affinity serotonin 5-HT4 receptor ligands based on quinoline structures., 9 (9): [PMID:30288221] [10.1039/C8MD00233A] |
| 67. HESI Myocyte Subteam: Blinova K., Brock M., Dang Q., Entcheva E., Feaster T.K., Gintant G., Guo, L., Herron T., Kanda Y., Kettenhofen R., Kraushaar U., Lu H.R., Lu J., Millard D., Objero-Paz C., Osada T., Pang L., Pierson J., Sawada K., Sekino Y., Shi H., Smith G., Snodgrass R., Stockbridge N., Strauss D.G., Traebert M., Wakatsuki T., Wu J., Zeng H., Zhang X.. (2019) Evaluation of the utility of stem-cell derived cardiomyocytes for drug proarrhythmic potential, [10.6019/CHEMBL4295262] |
| 68. Unpublished dataset, |
| 69. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 70. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 71. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 72. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 73. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 74. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
